Hi @chucke,
yes, it can feel that way. My personal view is that all IP becomes a dogfight at some point. And when you get to that point it’s best to have as many irons in the fire as possible, including PCT claims.
But I think the best way to look at China is through the eyes of a possible territory-specific collaboration licence with, oh I don’t know-say-Tasly.
If one had the necessary patent applications on the books able to be licensed or sub-licensed in-country, a potential competitor in China could become a potential competitive advantage in China.
Food for thought.
Cheers, GLTAH
Cell Therapy News/Articles, page-17374
-
- There are more pages in this discussion • 447 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |